Key Genes Associated with Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma with Metabolic Risk Factors

Overview

Journal Front Genet

Date 2023 Mar 23

PMID 36950134

Authors

Fan Yang

Beibei Ni

Qinghai Lian

Xiusheng Qiu

Yizhan He

Qi Zhang

Xiaoguang Zou

Fangping He

Wenjie Chen

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) has become the world's primary cause of cancer death. Obesity, hyperglycemia, and dyslipidemia are all illnesses that are part of the metabolic syndrome. In recent years, this risk factor has become increasingly recognized as a contributing factor to HCC. Around the world, non-alcoholic fatty liver disease (NAFLD) is on the rise, especially in western countries. In the past, the exact pathogenesis of NAFLD that progressed to metabolic risk factors (MFRs)-associated HCC has not been fully understood. Two groups of the GEO dataset (including normal/NAFLD and HCC with MFRs) were used to analyze differential expression. Differentially expressed genes of HCC were verified by overlapping in TCGA. In addition, functional enrichment analysis, modular analysis, Receiver Operating Characteristic (ROC) analysis, LASSO analysis, and Genes with key survival characteristics were analyzed. We identified six hub genes (FABP5, SCD, CCL20, AGPAT9(GPAT3), PLIN1, and IL1RN) that may be closely related to NAFLD and HCC with MFRs. We constructed survival and prognosis gene markers based on FABP5, CCL20, AGPAT9(GPAT3), PLIN1, and IL1RN.This gene signature has shown good diagnostic accuracy in both NAFLD and HCC and in predicting HCC overall survival rates. As a result of the findings of this study, there is some guiding significance for the diagnosis and treatment of liver disease associated with NAFLD progression.

Citing Articles

PLIN1 suppresses glioma progression through regulating lipid metabolism.

Luo K, Zhuang K, Wu H, Chen Y, Liu Y, Yang F Cell Death Dis. 2025; 16(1):48.

PMID: 39870645 PMC: 11772837. DOI: 10.1038/s41419-025-07347-z.

Clinical pathological significance and biological function of PLIN1 in hepatocellular carcinoma: bioinformatics analysis and in vitro experiments.

Huang J, Wei Y, Fang Z, Yu C, Zhang R, Feng Z BMC Cancer. 2024; 24(1):1073.

PMID: 39215210 PMC: 11363539. DOI: 10.1186/s12885-024-12842-1.

Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.

Anbarasu C, Williams-Perez S, Camp E, Erstad D Cancers (Basel). 2024; 16(16).

PMID: 39199546 PMC: 11352989. DOI: 10.3390/cancers16162773.

Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.

Chen X, Peng R, Peng D, Liu D, Li R J Transl Med. 2024; 22(1):701.

PMID: 39075482 PMC: 11288106. DOI: 10.1186/s12967-024-05506-y.

Prediagnostic plasma proteomics profile for hepatocellular carcinoma.

Zhang X, Zhao L, Ngo L, Dillon S, Gu X, Lai M J Natl Cancer Inst. 2024; 116(8):1343-1355.

PMID: 38688524 PMC: 11308170. DOI: 10.1093/jnci/djae079.

References

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Mancina R, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R . The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology. 2016; 150(5):1219-1230.e6. PMC: 4844071. DOI: 10.1053/j.gastro.2016.01.032. View

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

Carr R, Ahima R . Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res. 2015; 340(2):187-92. PMC: 4744586. DOI: 10.1016/j.yexcr.2015.10.021. View

Agosti P, Sabba C, Mazzocca A . Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(2):607-617. DOI: 10.1016/j.bbadis.2017.11.026. View

Enooku K, Tsutsumi T, Kondo M, Fujiwara N, Sasako T, Shibahara J . Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. J Gastroenterol. 2019; 55(2):227-243. DOI: 10.1007/s00535-019-01633-2. View

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W . Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22(1):63. PMC: 8919523. DOI: 10.1186/s12902-022-00980-1. View

Pihlajamaki J, Kuulasmaa T, Kaminska D, Simonen M, Karja V, Gronlund S . Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2011; 56(3):663-70. DOI: 10.1016/j.jhep.2011.10.005. View

Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y . Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018; 68(3):1025-1041. DOI: 10.1002/hep.29904. View

10.

Liu J, Sun B, Guo K, Yang Z, Zhao Y, Gao M . Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma. Cancer Gene Ther. 2022; 29(12):1951-1960. DOI: 10.1038/s41417-022-00510-0. View

11.

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

12.

Heagerty P, Lumley T, Pepe M . Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-44. DOI: 10.1111/j.0006-341x.2000.00337.x. View

13.

Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford A . Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020; 38(21):2380-2389. PMC: 7367550. DOI: 10.1200/JCO.20.00437. View

14.

Zhang J, Liu X, Zhou W, Lu S, Wu C, Wu Z . Identification of Key Genes Associated With the Process of Hepatitis B Inflammation and Cancer Transformation by Integrated Bioinformatics Analysis. Front Genet. 2021; 12:654517. PMC: 8440810. DOI: 10.3389/fgene.2021.654517. View

15.

Arendt B, Comelli E, Ma D, Lou W, Teterina A, Kim T . Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015; 61(5):1565-78. DOI: 10.1002/hep.27695. View

16.

Liu F, Liu W, Zhou S, Yang C, Tian M, Jia G . Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer. 2020; 8(2). PMC: 7332195. DOI: 10.1136/jitc-2019-000501. View

17.

Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y . Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. J Gastroenterol. 2016; 51(9):910-22. DOI: 10.1007/s00535-015-1159-8. View

18.

George B, Seals S, Aban I . Survival analysis and regression models. J Nucl Cardiol. 2014; 21(4):686-94. PMC: 4111957. DOI: 10.1007/s12350-014-9908-2. View

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

20.

Frades I, Andreasson E, Mato J, Alexandersson E, Matthiesen R, Martinez-Chantar M . Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease. PLoS One. 2015; 10(5):e0124544. PMC: 4439034. DOI: 10.1371/journal.pone.0124544. View